PheneX Pharmaceuticals AG
PheneX Pharmaceuticals AG is a German biotech start-up formed by a management buy-out of certain drug discovery assets from Lion Bioscience. The firm has embraced a fee-for-service business model, aiming to leverage its expertise in nuclear receptor modulating compounds.
You may also be interested in...
immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.
Lion's global SRS licensing deals with Eli Lilly and Johnson & Johnson in January endorse the company's decision to abandon drug discovery and focus on its bioinformatics roots.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.